Study the Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects With Coronary Heart Disease.

Trial Profile

Study the Effect of CYP3A Genetic Polymorphisms on the Pharmacokinetics of Atorvastatin in Chinese Subjects With Coronary Heart Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2013

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Coronary artery disease
  • Focus Pharmacokinetics
  • Acronyms ECGPPA
  • Most Recent Events

    • 28 Nov 2011 Trial phase changed from II to I and actual patient number is 20 as reported by ClinicalTrials.gov.
    • 28 Nov 2011 Actual end date Mar 2011 added as reported by ClinicalTrials.gov.
    • 28 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top